OSR Health says Nasdaq didn't approve loyalty program
OSR Health stated that a previous Nasdaq communication regarding its Shareholder Loyalty CVR Program was a preliminary technical inquiry only and did not constitute an endorsement …
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
OSR Health stated that a previous Nasdaq communication regarding its Shareholder Loyalty CVR Program was a preliminary technical inquiry only and did not constitute an endorsement …
Citibank Credit Card Master Trust I filed an 8-K report updating information relating to its credit card receivables and accounts. The filing outlines specific terms regarding the …
The FDA issues an Emergency Use Authorization for CLiK Extra wound spray to prevent infestations in livestock including cattle, goats, and swine.
The company's 2026 annual meeting was adjourned without a quorum, meaning directors and auditors will hold over until a subsequent vote is held.
The company filed a registration statement on Form S-1 for $691.7 million of outstanding $700 million convertible notes. Holders are invited to voluntarily register their notes in …
Grayscale Sui Staking ETF amended its trust agreement to clarify the definition of staking and remove terms deemed unlawful under IRS Revenue Procedure 2025-31. The changes apply t…
Grayscale has filed a Third Amended and Restated Declaration of Trust effective August 6, 2026. This regulatory update confirms the stewardship agreement between the Trust, the Spo…
The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy, for advanced, refractory melanoma.
Bunker Hill Mining Corp. filed an amended and restated bylaws with the SEC, formalizing its corporate governance structure. This typically streamlines operations and shareholder ri…
Olenox Industries confirmed receipt of notice from Nasdaq on August 6, 2026, stating it has regained compliance with Listing Rule 5250(c)(1) following the timely filing of its Form…
The company reports rapid clinical improvements in all ten patients from its FORWARD study for tanruprubart. The positive trial data reinforce the drug's potential to become the fi…
Corbus Pharmaceuticals secured FDA clearance for the Phase 3 TEMPO-1 study of CRB-701 in oropharyngeal cancer and announced leadership appointments to advance its clinical pipeline…
Intellia released positive Phase 3 data for its HAE treatment lonvo-z, received FDA guidance, and ended the quarter with strong liquidity.
Sionna Therapeutics has voluntarily withdrawn its New Drug Application for STX001, which had a Prescription Drug User Fee Act date, to conduct a strategic business review. The comp…
REGENXBIO reported strong second-quarter results, announcing the initiation of RGX-202 BLA filing and up to ~2H 2027 catalyst expectations, extending its cash runway consistent wit…
The FDA approved Orzeyful tablets for the treatment of narcolepsy type 1 in adults.
Gary Cheng CPA Limited agrees with internal controls statements but cannot comment on remediation timing or board seats. The firm provided a no-opinion letter.
Duke Energy Progress settled its 2025 North Carolina rate case with the NCUC, approving a 15.1% revenue increase over two years and a 9.8% rate of return, key for regulating earnin…
Flowserve filed Amended and Restated bylaws effective Aug. 5, 2026. The amendment outlines specific procedures for special shareholder meetings and the locations of the principal b…
The company announced FDA acceptance for its first NDA for daraxonrasib and updated clinical progress in oncology.